China approves Eli Lilly oral weight-loss drug orforglipron
Briefing by News4U · First published
SCMP Business reported that China's National Medical Products Administration approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, marketed as Foundayo, for chronic weight management in obese or overweight adults. [1]
Sources
- Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
SCMP Business · · Summary only